These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 16845332

  • 21. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
    Kim KB, Hwu WJ, Papadopoulos NE, Bedikian AY, Camacho LH, Ng C, Hernandez IM, Frost AM, Jack MA, Hwu P.
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):161-7. PubMed ID: 19002462
    [Abstract] [Full Text] [Related]

  • 22. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
    Lewis KD, Gibbs P, O'Day S, Richards J, Weber J, Anderson C, Zeng C, Baron A, Russ P, Gonzalez R.
    Cancer Invest; 2005 Jun; 23(4):303-8. PubMed ID: 16100942
    [Abstract] [Full Text] [Related]

  • 23. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
    Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, Williams LJ, Chapman PB, Livingston PO, Wolchok JD, Houghton AN.
    Cancer; 2006 Jun 01; 106(11):2445-51. PubMed ID: 16639739
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.
    Clin Cancer Res; 2000 Apr 01; 6(4):1267-72. PubMed ID: 10778950
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
    Fateh S, Schell TD, Gingrich R, Neves RI, Drabick JJ.
    Cancer Biol Ther; 2010 Dec 01; 10(11):1091-7. PubMed ID: 20930514
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma.
    Andrès P, Cupissol D, Guillot B, Avril MF, Drèno B.
    Eur J Dermatol; 1998 Jun 01; 8(4):235-9. PubMed ID: 9649695
    [Abstract] [Full Text] [Related]

  • 31. [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
    Frick S, Lischner S, Rosien F, Haacke TC, Schäfer F, Christophers E, Hauschild A.
    Hautarzt; 2002 Oct 01; 53(10):659-65. PubMed ID: 12297947
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
    Xia C, Leon-Ferre R, Laux D, Deutsch J, Smith BJ, Frees M, Milhem M.
    Cancer Chemother Pharmacol; 2014 Oct 01; 74(4):691-7. PubMed ID: 25062770
    [Abstract] [Full Text] [Related]

  • 34. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS.
    J Clin Oncol; 2009 Dec 20; 27(36):6207-12. PubMed ID: 19917850
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
    Hwu WJ, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, Williams LJ, Quinn CJ, Foster T, Chapman PB, Livingston PO, Wolchok JD, Houghton AN.
    J Clin Oncol; 2003 Sep 01; 21(17):3351-6. PubMed ID: 12947072
    [Abstract] [Full Text] [Related]

  • 39. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
    Ranson M, Hersey P, Thompson D, Beith J, McArthur GA, Haydon A, Davis ID, Kefford RF, Mortimer P, Harris PA, Baka S, Seebaran A, Sabharwal A, Watson AJ, Margison GP, Middleton MR.
    J Clin Oncol; 2007 Jun 20; 25(18):2540-5. PubMed ID: 17577032
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.